Acyclovir in the treatment of recurrent respiratory papillomatosis: A preliminary report

Kıroğlu, Mete; Çetik, Fikret; Soylu, Levent; Abedi, Ali; Aydoǧan, Barlas; Akçalı, Çağatay; Kıroǧlu, Fikret; Özşahinoǧlu, Can

doi:10.1016/0196-0709(94)90007-8

Cited by 29 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Adjuvant pharmacotherapy is used in up to 30 % of pediatric patients with RRP, with cidofovir and interferon alpha being applied in more than two-thirds of the cases [14,15,17,18]. Other antiviral drugs (e.g., acyclovir and valacyclovir), and indole-3-carbinol were also used in small series [1,2,16,[19][20][21][22]. According to a limited number of studies, the effective management of laryngopharyngeal reflux may also result in an improved control of RRP [12,23].…”

Section: Introductionmentioning

confidence: 99%

Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis

Boltežar

Matičič

Šereg-Bahar

et al. 2014

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

In the case of an aggressive course of recurrent respiratory papillomatosis (RRP), adjuvant therapy can be used besides surgery. The aim of the study was to investigate the influence of vaccination with a quadrivalent vaccine against human papilloma viruses (HPV) types 6, 11, 16 and 18 on the course of RRP. Eleven subjects aged 13-46 years with a rapid growth of laryngeal papillomas were included in the study. They were vaccinated with three doses of the quadrivalent prophylactic HPV vaccine (Silgard(®), MSD) and followed up for 12-52 months. The intervals between the successive surgical procedures, the extension of the disease (Derkay score) at each surgery, and the number of surgical procedures per year before vaccination and after its completion were compared. The mean interval between the surgical procedures was 271.2 days before the vaccination and 537.4 days after it (p = 0.034). The mean number of surgeries per year was 2.16 before the vaccination and 0.93 after it (p = 0.022). The Derkay score did not change significantly after vaccination. Complete remission of the disease was observed in one patient, partial response to the vaccination was observed in seven patients and no response was observed in three patients. In conclusion, vaccination with the quadrivalent HPV vaccine can favorably influence the course of RRP in patients with the rapid growth of the papillomas. It significantly prolongs the intervals between the surgical procedures and reduces the number of procedures needed in the majority of patients. The present investigation can serve as a pilot study for further research. For a final conclusion a longer follow-up and studies on more patients are necessary.

show abstract

Section: Introductionmentioning

confidence: 99%

Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis

Boltežar

Matičič

Šereg-Bahar

et al. 2014

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…Antiviral drugs used in the treatment of RRP have been acyclovir, cidofovir, and ribavirin. The majority of patients treated with acyclovir were free of the disease during a follow-up period of at least 1 year in the study reported by Kiroglu et al [38]. Some decrease in the extent of respiratory papillomatosis in patients with persistent disease was reported by Endres et al [22].…”

Section: Adjuvant Drug Therapiesmentioning

confidence: 86%

Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis

Bergler

Götte

2000

European Archives of Oto-Rhino-Laryngology

View full text Add to dashboard Cite

Juvenile-onset recurrent respiratory papillomatosis is a relatively uncommon disease that presents clinically with symptoms ranging from hoarseness to severe dyspnea. Human papilloma viruses type 6 and 11 are important in the etiology of the papillomata and are most probably transmitted from mother to child during childbirth. Although spontaneous remission is frequent, a rare fatal course because of pulmonary spread or malignant transformation has occurred. CO2 laser evaporation of papillomas and adjuvant drug therapy using lymphoblastoid alpha-interferon are the most common treatment modalities at present. However, several other treatment modalities have been tried with varying success. Recent advances in basic research and different therapeutic approaches are reviewed.

show abstract

“…Acyclovir: The regimens used are different (10 mg/kg 5Â/day for10 days then bid Â 6 weeks) (400-800 mg/day Â 6 months) and so are the results [36][37][38][39]. Its mode of action in this context is unclear.…”

Section: Reviewmentioning

confidence: 99%

Can zinc be an adjuvant therapy for juvenile onset recurrent respiratory papillomatosis?

Bitar

Baz

Fuleihan

et al. 2007

International Journal of Pediatric Otorhinolaryngology

View full text Add to dashboard Cite

Acyclovir in the treatment of recurrent respiratory papillomatosis: A preliminary report

Cited by 29 publications

References 8 publications

Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis

Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis

Current advances in the basic research and clinical management of juvenile-onset recurrent respiratory papillomatosis

Can zinc be an adjuvant therapy for juvenile onset recurrent respiratory papillomatosis?

Contact Info

Product

Resources

About